Bionomics

Bionomics Limited engages in the discovery and development of therapeutics for cancer and diseases of the central nervous system in Australia. It has small molecule product development programs in the areas of cancer, anxiety, epilepsy, and multiple sclerosis. The company develops its lead cancer compound, BNC 105, for the treatment of solid tumors, such as breast, lung, colon, and prostate cancers. BNC 105 is a member of the class of compounds, known as vascular disruption agents or VDAs, which shut down the blood supply within a tumor, starving the tumor and preventing its continued growth. The company has commercial partnerships with Genmab A/S; Athena Diagnostics; Laboratory Corporation of America; and Genetic Technologies, Ltd. Bionomics Limited was founded in 1999 and is based in Thebarton, Australia.

Tim Cunningham

CFO

3 past transactions

Prestwick Chemical

Acquisition in 2014
Prestwick Chemical offers smart chemical screening libraries, medicinal chemistry services to accelerate development of innovative small molecule drugs. Prestwick Chemical is a French Contract Research Organization (CRO) founded in 1999 by Professor C.G. Wermuth, globally recognized for his expertise in pharmacology and medicinal chemistry. Focused on early drug discovery, the company works for pharmaceutical and biotechnology companies, research institutes as well as academic groups. Projects in cosmetics, veterinary and agro pharmaceutical are also successfully carried on. During the past decade, Prestwick Chemical has gained international recognition for its input to boost drug discovery process through: Tailor-made medicinal chemistry services Smart chemical screening libraries

Eclipse Therapeutics

Acquisition in 2012
Eclipse Therapeutics, Inc. ("Eclipse") is a private biotechnology company dedicated to the discovery and development of therapeutics that target cancer stem cells (CSCs) and other forms of innovative cancer treatment.

Iliad Chemicals Pty

Acquisition in 2005
Iliad Chemicals Pty Limited develops a library of novel molecules that act as potent tubulin polymerisation inhibitors for treating cancer. The company utilizes MultiCore Chemistry technology platform to provide synthesis of molecules and develop chemical libraries.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.